A Study to Determine the Antitumor Activity and Evaluate the Safety of MKC-1

Inclusion criteria

• Histologically or cytologically confirmed advanced or metastatic adenocarcinoma of the breast
• 18 years or older
• Karnofsky performance status greater than or equal to 70%
• Radiographic or physical examination evidence of at least one site of unidimensionally-measurable disease, using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria
• Must have failed both a taxane and an anthracycline, given sequentially or in combination, either in an adjuvant or metastatic setting
• All acute toxicity of any prior chemotherapy, surgery or radiotherapy must have resolved to National Cancer Institute Common Toxicity Criteria (NCI CTC) Grade less than or equal to 1
• Lab results, within 10 days of MKC-1 administration:

• Hemoglobin less than or equal to 9 g/dL
• Absolute neutrophil count greater than or equal to 1.5 x 10^9/L
• Platelet count greater than or equal to 75 x 10^9/L
• Serum creatinine less than or equal to 1.5 x ULN (upper limit of normal)
• AST less than or equal to 2.5 x ULN
• Serum albumin greater than or equal to LLN (lower limit of normal)
• Total bilirubin less than or equal to ULN
• Alkaline phosphatase less than or equal to 2.5 x ULN
• Signed informed consent

Exclusion criteria

• Pre-existing hepatomegaly with disease measures greater than or equal to 2 cm below the costal margin, secondary to malignancy
• Administration of cancer specific therapy within the following periods prior to study drug initiation:

• chemotherapy less than 3 weeks prior
• hormonal therapy less than one week prior
• radiation therapy less than 2 weeks prior
• Be pregnant or lactating; not employing effective birth control
• Known central nervous system (CNS) metastases unless treated, clinically stable and not requiring steroids
• Clinical evidence of bowel obstruction, active uncontrolled malabsorption syndromes or a history of total gastrectomy
• Administration of any investigational agent (therapeutic or diagnostic) within 4 weeks prior to receipt of study medication
• Uncontrolled hypercalcemia (serum calcium-corrected greater than 12 mg/dL)
• Serious cardiac condition
• Any medical conditions that, in the investigator's opinion would impose excessive risk to the patient
• Patients with previous malignancies unless free of recurrence for at least 5 years except basal cell carcinoma of the skin or carcinoma-in-situ of the uterine cervix
• Treatment with antiretroviral therapy metabolized through CYP3A4